Aptuit To Purchase Quintiles
In a $125-million deal, Aptuit (Greenwich, CN) has agreed to buy three Quintiles Transnational (Research Triangle Park, NC) business units: the Pharmaceutical Sciences contract manufacturing and formulation development group, the Packaging and Logistics group, and the Preclinical Services group.
The three units now employ 1,400 (primarily in Kansas City, MO; Mt. Laurel, NJ; Edinburgh, Scotland, and Singapore) and provide services to 19 of the world's 20 largest drug companies, according to a joint statement issued Tuesday.
The statement quoted Aptuit CEO Michael A. Griffith as saying, "These business lines constitute a premier business that will form the foundation for our comprehensive drug development services offering. We gain an industry-leading team with the right expertise for our business model, a world-class customer base, GMP/GLP facilities, and a range of technologies to support and help drive drug development. From a technical and operational standpoint, the transition to Aptuit will be virtually seamless to employees and customers."
Aptuit reportedly intends to invest $50 million in reorganizing and developing the acquired businesses over the next several years.
The deal also includes a multi-year joint-marketing deal between the two companies.
–Douglas McCormick
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.